5T4/TPBG recombinant proteins and antibodies

Oncofetal protein 5T4, also known as Wnt activation inhibitory factor 1 (WAIF1) and trophoblast cell glycoprotein (TPBG), is a glycoprotein present in embryonic trophoblast cells. 5T4 is rarely expressed in normal adult tissues, but is widely expressed in various trophoblast cells during embryonic development and most common tumors. It is highly expressed in about 80% of renal cancer, breast cancer, colon cancer, prostate cancer and ovarian cancer. Due to the differential expression of 5T4 in normal tissues and cancer tissues, 5T4 can be used as a tumor treatment target with potential therapeutic value. However, there is still little understanding of the mechanism of action of this molecule in tumors. However, existing studies have shown that 5T4 may act through the Wnt signaling pathway, epithelial-mesenchymal transition and CXCR4/CXCL12 pathway. More about 5T4 mechanism of action and signaling pathways >>

According to Clinical trial data, there are currently about 9 5T4 drugs under development, and there are only nearly 20 clinical pipelines, but the types of drugs are relatively diverse, involving tumor vaccines, fusion proteins, ADCs, bispecific antibodies, and CAR-NK. Among them, tumor vaccines (Trovax) and fusion proteins (Naptumomab estafenatox) have made the fastest progress, and the highest research and development status is currently in clinical phase II.

To assist in the development of targeted 5T4 biopharmaceuticals, DIMA BIOTECH relies on its self-developed innovative functional membrane protein development, single B cell lead antibody discovery, antibody engineering and functional verification platform, and can simultaneously provide a full range of 5T4 target products and services, including a variety of active proteins, flow cytometry-verified monoclonal antibodies and reference antibodies; services include humanization, affinity maturation, and PTM risk site removal. In addition, in order to accelerate the development of 5T4 target drugs, DIMA BIOTECH has also prepared a B cell seed library for 5T4, which can complete the screening of lead antibody molecules in as fast as 20 days.